Ngā hua rapu - Xu, Ximing
- E whakaatu ana i te 1 - 20 hua o te 87
- Haere ki te Whārangi Whai Ake
-
1
-
2
-
3
-
4
-
5
-
6
-
7
A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies mā Cao, Dedong, Xu, Huilin, Xu, Ximing, Guo, Tao, Ge, Wei
I whakaputaina 2018Text -
8
-
9
-
10
-
11
-
12
-
13
The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis mā Xu, Huilin, Xu, Ximing, Ge, Wei, Lei, Jinju, Cao, Dedong
I whakaputaina 2020Text -
14
-
15
-
16
Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells mā Rui, Mengjie, Qu, Yang, Gao, Tong, Ge, Yanru, Feng, Chunlai, Xu, Ximing
I whakaputaina 2016Text -
17
-
18
-
19
-
20
High-level Expression of Glycoprotein D by a Dominant-negative HSV-1 Virus Augments Its Efficacy as a Vaccine Against HSV-1 Infection mā Lu, Zheming, Brans, Richard, Akhrameyeva, Natali V., Murakami, Nao, Xu, Ximing, Yao, Feng
I whakaputaina 2008Text